论文部分内容阅读
目的观察阿奇霉素治疗小儿支原体肺炎的临床疗效及安全性。方法对160例支原体肺炎患儿随机分为治疗组(阿奇霉素治疗)88例和对照组(红霉素治疗)72例,比较两组退热时间,咳嗽好转时间,罗音消失时间,胸部X线阴影吸收时间,不良反应发生率。结果治疗组的退热时间,咳嗽好转时间,罗音消失时间和平均住院时间与对照组比较均明显缩短,不良反应发生率明显减少。两组间比较有显著性差异(P均<0.01)。结论阿奇霉素治疗小儿支原体肺炎疗效明显,安全可靠,值得在临床上推广应用。
Objective To observe the clinical efficacy and safety of azithromycin in treating children with mycoplasma pneumonia. Methods One hundred and sixty children with mycoplasma pneumonia were randomly divided into treatment group (azithromycin treatment group) and control group (erythromycin treatment group), and the control group (n = 72). The differences of fever relief time, cough time, Shadow absorption time, the incidence of adverse reactions. Results The antipyretic time, cough improvement time, rales disappearance time and average length of stay in the treatment group were significantly shortened compared with the control group, and the incidence of adverse reactions was significantly reduced. There was significant difference between the two groups (all P <0.01). Conclusion Azithromycin treatment of children with mycoplasma pneumonia obvious effect, safe and reliable, it is worth to promote the clinical application.